or
Looking to list your PhD opportunities? Log in here.
Professor Davide Calebiro studied Medicine in Milan and Stockholm, obtaining a Clinical Specialization in Endocrinology and Metabolic Diseases as well as a PhD in Molecular Medicine from the University of Milan. From 2009 to 2018, he led a research group at the Institute of Pharmacology and Bio-Imaging Center of Würzburg University, Germany. He joined the University of Birmingham in 2017, supported by a Birmingham Professorial Fellowship. In 2018, he was awarded a prestigious Wellcome Trust Senior Research Fellowship. Professor Calebiro is the Head of the Department of Metabolism and Systems Science and a Professor of Molecular Endocrinology. He is also a Wellcome Trust Senior Research Fellow and Co-Director of the Centre of Membrane Proteins and Receptors (COMPARE) at the Universities of Birmingham and Nottingham. His research team is multidisciplinary, comprising biologists, chemists, physicists, engineers, and computer scientists, focusing on G protein-coupled receptor (GPCR) signalling and its alterations in endocrine and metabolic diseases. His major scientific contributions include the discovery that GPCRs are active not only at the plasma membrane but also at intracellular sites, and that these receptors form dynamic nanodomains at the plasma membrane. He has published 80 research papers in prestigious scientific journals and serves on multiple panels and committees, including the Programme Committee of the Society for Endocrinology and the MRC Molecular & Cellular Medicine Board.
Professor Davide Calebiro''s research focuses on the basic mechanisms of G protein-coupled receptor (GPCR) signalling and their alterations in endocrine and metabolic diseases. He leads a multidisciplinary team that develops and employs innovative optical methods, such as FRET and single-molecule microscopy, to directly observe signalling events in living cells with high spatiotemporal resolution. His significant contributions include the discovery that GPCRs are active not only at the plasma membrane but also at intracellular sites, and that these receptors form dynamic nanodomains by interacting with each other and other membrane proteins. The research aims to advance understanding of GPCR signalling mechanisms to develop innovative pharmacological therapies for endocrine and metabolic diseases. The group also investigates genetic alterations in GPCR signalling, identifying genetic causes of diseases such as cortisol-secreting adrenocortical adenomas.
Prof Stephen Hill's profile is coming soon
View other supervisors at University of Birmingham